HCPCS code |
Brand Name |
Generic Name |
HCPCS Description |
Requirement |
Requirement Effective Date |
Clinical Category |
J3262 |
Actemra |
Tocilizumab |
Injection, Tocilizumab, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J0791 |
Adakveo |
Crizanlizumab-Tmca |
Injection, Crizanlizumab-Tmca, 5 mg |
PA Request |
4/1/23 |
Sickle Cell Disease |
J9042 |
Adcetris |
Brentuximab |
Injection, Brentuximab Vedotin, 1 mg |
PA Request |
4/1/23 |
Oncology |
J0172 |
Aduhelm |
Aducanumab-Avwa |
Injection, Aducanumab-avwa, 2 mg |
PA Request |
4/1/23 |
Antidementia Agent |
J9057 |
Aliqopa |
Copanlisib |
Injection, Copanlisib, 1 mg |
PA Request |
4/1/23 |
Oncology |
J2469 |
Aloxi |
Palonosetron hcl |
Injection, palonosetron hcl, 25 mcg |
No PA/No Precert Required |
N/A |
Anti-emetics |
J1426 |
Amondys 45 |
Casimersen |
Injection, Casimersen, 10 mg |
PA Request |
1/1/23 |
Duchenne Muscular Dystrophy (DMD) |
J0225 |
Amvuttra |
Vutrisiran |
Injection, Vutrisiran, 1 mg |
PA Request |
8/1/23 |
RNAi Therapy (hATTR amyloidosis) |
J2430 |
Aredia |
Pamidronate disodium |
Injection, pamidronate disodium, per 30 mg |
No PA/No Precert Required |
N/A |
Osteoporosis |
J9302 |
Arzerra |
Ofatumumab |
Injection, Ofatumumab, 10 mg |
PA Request |
4/1/23 |
Oncology |
J9035 |
Avastin |
Bevacizumab |
Injection, Bevacizumab, 10 mg |
PA Request |
4/1/23 |
Oncology |
Q5121 |
Avsola |
Infliximab-Axxq |
Injection, Infliximab-Axxq, biosimilar, (Avsola), 10mg |
PA Request |
8/1/23 |
Auto-Inflammatory Conditions |
J0490 |
Benlysta IV |
Belimumab |
Injection, Belimumab, 10 mg |
PA Request |
4/1/23 |
Systemic Lupus Erythematosus (SLE) |
J0179 |
Beovu |
Brolucizumab |
Injection, Brolucizumab-dbll, 1 mg |
PA Request |
4/1/23 |
Macular Degeneration |
J9229 |
Besponsa |
Inotuzumab Ozogamicin |
Injection, Inotuzumab ozogamicin, 0.1 mg |
PA Request |
4/1/23 |
Oncology |
C9142 |
Bevacizumab (Alymsys) |
Bevacizumab-maly |
Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg |
No PA/No Precert Required |
N/A |
Oncology |
J9039 |
Blincyto |
Blinatumomab |
Injection, Blinatumomab, 1 microgram |
PA Request |
4/1/23 |
Oncology |
J1740 |
Boniva |
Ibandronate sodium |
Injection, ibandronate sodium, 1 mg |
No PA/No Precert Required |
N/A |
Osteoporosis |
J0585 |
Botox |
Onabotulinumtoxina |
Injection, Onabotulinumtoxina, 1 unit |
PA Request |
4/1/23 |
Neurotoxin |
J0567 |
Brineura |
Cerliponase Alfa |
Injection, Cerliponase alfa, 1 mg |
PA Request |
4/1/23 |
Enzyme Deficiency |
Q5124 |
Byooviz |
Ranibizumab-Nuna |
Injection, Ranibizumab-nuna, biosimilar, (Byooviz), 0.1 mg |
PA Request |
8/1/23 |
Macular Degeneration |
J0741 |
Cabenuva |
Cabotegravir/Rilpivirine |
Injection, Cabotegravir and Rilpivirine, 2mg/3mg |
PA Request |
4/1/23 |
HIV/AIDS |
J1786 |
Cerezyme |
Imiglucerase |
Injection, Imiglucerase, 10 units |
PA Request |
4/1/23 |
Enzyme Deficiency |
J0717 |
Cimzia |
Certolizumab |
Injection, Certolizumab Pegol, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J2786 |
Cinqair |
Reslizumab |
Injection, Reslizumab, 1 mg |
PA Request |
4/1/23 |
Asthma |
J0584 |
Crysvita |
Burosumab |
Injection, Burosumab-twza 1 mg |
PA Request |
4/1/23 |
Metabolic Conditions |
J9308 |
Cyramza |
Ramucirumab |
Injection, Ramucirumab, 5 mg |
PA Request |
4/1/23 |
Oncology |
J9348 |
Danyelza |
Naxitamab-Gqgk |
Injection, Naxitamab-gqgk, 1 mg |
PA Request |
4/1/23 |
Oncology |
J9145 |
Darzalex |
Daratumumab |
Injection, Daratumumab 10 mg |
PA Request |
4/1/23 |
Oncology |
J9144 |
Darzalex Faspro |
Daratumumab / Hyaluronidase-Fihj |
Injection, Daratumumab, 10 mg and hyaluronidase-fihj |
PA Request |
4/1/23 |
Oncology |
J7318 |
Durolane |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg |
PA Request |
4/1/23 |
Osteoarthritis |
J0586 |
Dysport |
Abobotulinumtoxina |
Injection, Abobotulinumtoxina, 5 units |
PA Request |
4/1/23 |
Neurotoxin |
J3060 |
Elelyso |
Taliglucerase Alfa |
Injection, Taliglucerase alfa, 10 units |
PA Request |
4/1/23 |
Enzyme Deficiency |
J9176 |
Empliciti |
Elotuzumab |
Injection, Elotuzumab, 1mg |
PA Request |
4/1/23 |
Oncology |
J1438 |
Enbrel |
Etanercept |
Injection, Etanercept, 25 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J9358 |
Enhertu |
Fam-Trastuzumab Deruxtecan-Nxki |
Injection, Fam-trastu deru-nxki 1mg |
PA Request |
4/1/23 |
Oncology |
J3380 |
Entyvio |
Vedolizumab |
Injection, Vedolizumab, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J0885 |
Epogen/Procrit |
Epoetin Alfa |
Injection, Epoetin Alfa, (for non-ESRD use), 1000 units |
PA Request |
4/1/23 |
Anemia |
Q4081 |
Epogen/Procrit |
Epoetin Alfa |
Injection, Epoetin Alfa, 100 units (for ESRD on dialysis) |
PA Request |
4/1/23 |
Anemia (Dialysis) |
J9055 |
Erbitux |
Cetuximab |
Injection, Cetuximab, 10 Mg |
PA Request |
4/1/23 |
Oncology |
J7323 |
Euflexxa |
Hyaluronan or derivative |
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose |
No PA/No Precert Required |
N/A |
Osteoarthritis |
J3111 |
Evenity |
Romosozumab |
Injection, Romosozumab-aqqg 1 mg |
PA Request |
4/1/23 |
Osteoporosis |
J1428 |
Exondys 51 |
Eteplirsen |
Injection, Eteplirsen, 10 mg |
PA Request |
1/1/23 |
Duchenne Muscular Dystrophy (DMD) |
J0178 |
Eylea |
Aflibercept |
Injection, Aflibercept, 1 mg |
PA Request |
4/1/23 |
Macular Degeneration |
J0517 |
Fasenra |
Benralizumab |
Injection, Benralizumab, 1 mg |
PA Request |
4/1/23 |
Asthma |
Q0138, Q0139 |
Feraheme |
Ferumoxytol |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
No PA/No Precert Required |
N/A |
Anemia |
J2916 |
Ferrlecit |
Sodium Ferric Gluconate |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
No PA/No Precert Required |
N/A |
Anemia |
J9155 |
Firmagon |
Degarelix |
Injection, Degarelix, 1 mg |
PA Request |
4/1/23 |
Oncology |
J9307 |
Folotyn |
Pralatrexate |
Injection, Pralatrexate, 1 mg |
PA Request |
4/1/23 |
Oncology |
Q5108 |
Fulphila |
Pegfilgrastim-Jmdb |
Injection, Pegfilgrastim-jmdb (Fulphila), biosimilar, 0.5 mg |
PA Request |
8/1/23 |
Neutropenia |
J9301 |
Gazyva |
Obinutuzumab |
Injection, Obinutuzumab, 10 mg |
PA Request |
4/1/23 |
Oncology |
J7326 |
Gel-One |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Gel-one, for intra-articular injection, per dose |
PA Request |
4/1/23 |
Osteoarthritis |
J7328 |
Gelsyn-3 |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Gelsyn-3, for intra-articular injection, 0.1 mg |
PA Request |
4/1/23 |
Osteoarthritis |
J7320 |
Genvisc 850 |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Genvisc 850, for intra-articular injection, 1 mg |
PA Request |
4/1/23 |
Osteoarthritis |
J9179 |
Halaven |
Eribulin Mesylate |
Injection, Eribulin mesylate, 0.1 mg |
PA Request |
4/1/23 |
Oncology |
J7170 |
Hemlibra |
Emicizumab |
Injection, Emicizumab-kxwh, 0.5 mg |
PA Request |
4/1/23 |
Hemophilia |
J9355 |
Herceptin |
Trastuzumab |
Injection, Trastuzumab, excludes biosimilar, 10 mg |
PA Request |
4/1/23 |
Oncology |
J9356 |
Herceptin Hylecta |
Trastuzumab / Hyaluronidase-Oysk |
Injection, Trastuzumab, 10 mg and hyaluronidase-oysk |
PA Request |
4/1/23 |
Oncology |
Q5113 |
Herzuma |
Trastuzumab-pkrb |
Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg |
No PA/No Precert Required |
N/A |
Oncology |
J0135 |
Humira |
Adalimumab |
Injection, Adalimumab, 20 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J7321 |
Hyalgan |
Hyaluronan or derivative |
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose |
No PA/No Precert Required |
N/A |
Osteoarthritis |
J7322 |
Hymovis |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg |
PA Request |
4/1/23 |
Osteoarthritis |
J0638 |
Ilaris |
Canakinumab |
Injection, Canakinumab, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J3245 |
Ilumya |
Tildrakizumab |
Injection, Tildrakizumab, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J7313 |
Iluvien |
Fluocinolone Acetonide |
Injection, Fluocinolone Acetonide intravitreal implant, 0.01 mg |
PA Request |
4/1/23 |
Ophthalmic Disorders |
J9173 |
Imfinzi |
Durvalumab |
Injection, Durvalumab, 10 mg |
PA Request |
4/1/23 |
Oncology |
J9325 |
Imlygic |
Talimogene Laherparepvec |
Injection, Talimogene Laherparepvec, per 1 million plaque forming units |
PA Request |
1/1/23 |
Auto-Inflammatory Conditions |
J1750 |
Infed |
Iron Dextran |
Injection, iron dextran, 50 mg |
No PA/No Precert Required |
N/A |
Anemia |
Q5103 |
Inflectra |
Infliximab–Dyyb |
Injection, Infliximab-Dyyb, biosimilar, (Inflectra), 10 mg |
PA Request |
8/1/23 |
Auto-Inflammatory Conditions |
J1439 |
Injectafer |
Ferric Carboxymaltose |
Injection, Ferric Carboxymaltose, 1 mg |
PA Request |
4/1/23 |
Anemia |
Q5109 |
Ixifi |
Infliximab-qbtx |
Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg |
No PA/No Precert Required |
N/A |
Auto-inflammatory Conditions |
J9354 |
Kadcyla |
Ado-Trastuzumab Emtansine |
Injection, Ado-trastuzumab emtansine, 1 mg |
PA Request |
4/1/23 |
Oncology |
Q5117 |
Kanjinti |
Trastuzumab-anns |
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
No PA/No Precert Required |
N/A |
Oncology |
J2425 |
Kepivance |
Palifermin |
Injection, Palifermin 50 mg |
PA Request |
4/1/23 |
Oncology |
J9271 |
Keytruda |
Pembrolizumab |
Injection, Pembrolizumab, 1 mg |
PA Request |
4/1/23 |
Oncology |
J2507 |
Krystexxa |
Pegloticase |
Injection, Pegloticase, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J9047 |
Kyprolis |
Carfilzomib |
Injection, Carfilzomib, 1 mg |
PA Request |
4/1/23 |
Oncology |
J1626 |
Kytril |
Granisetron hydrochloride |
Injection, granisetron hydrochloride, 100 mcg |
No PA/No Precert Required |
N/A |
Anti-emetics |
J1932 |
Lanreotide |
Lanreotide |
Injection, lanreotide, (cipla), 1 mg |
No PA/No Precert Required |
N/A |
Endocrine Disorders |
J0202 |
Lemtrada |
Alemtuzumab |
Injection, Alemtuzumab, 1 mg |
PA Request |
4/1/23 |
Multiple Sclerosis |
J1306 |
Leqvio |
Inclisiran |
Injection, Inclisiran, 1 mg |
PA Request |
4/1/23 |
Hypercholesterolemia |
J9119 |
Libtayo |
Cemiplimab-Rwlc |
Injection, Cemiplimab-rwlc, 1 mg |
PA Request |
4/1/23 |
Oncology |
J2778 |
Lucentis |
Ranibizumab |
Injection, Ranibizumab, 0.1 mg |
PA Request |
4/1/23 |
Macular Degeneration |
J0221 |
Lumizyme |
Alglucosidase Alfa |
Injection, Alglucosidase alfa, (lumizyme), 10 mg |
PA Request |
4/1/23 |
Enzyme Deficiency |
J1950 |
Lupron Depot |
Leuoprolide Acetate |
Injection, Leuprolide acetate (for depot suspension), per 3.75 mg |
PA Request |
4/1/23 |
Oncology |
J1954 |
Lutrate |
Leuprolide Acetate |
Injection, Leuprolide Acetate for depot suspension (lutrate), 7.5 mg |
PA Request |
8/1/23 |
Oncology |
J3398 |
Luxturna |
Voretigene Neparvovec |
Injection, Voretigene Neparvovec-rzyl, 1 billion vector genomes |
PA Request |
4/1/23 |
Leber Congenital Amaurosis |
J2503 |
Macugen |
Pegaptanib |
Injection, Pegaptanib sodium, 0.3 mg |
PA Request |
4/1/23 |
Macular Degeneration |
J1726 |
Makena |
Hydroxyprogesterone Caproate |
Injection, Hydroxyprogesterone Caproate, (makena), 10 mg |
PA Request |
4/1/23 |
Endocrine Disorders |
J9349 |
Monjuvi |
Tafasitamab-Cxix |
Injection, Tafasitamab-cxix |
PA Request |
4/1/23 |
Oncology |
J1437 |
Monoferric |
Ferric Derisomaltose |
Injection, Ferric Derisomaltose, 10 mg |
PA Request |
4/1/23 |
Anemia |
J7327 |
Monovisc |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose |
PA Request |
4/1/23 |
Osteoarthritis |
Q5107 |
Mvasi |
Bevacizumab-Awwb |
Injection, Bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
PA Request |
8/1/23 |
Oncology |
J0587 |
Myobloc |
Rimabotulinumtoxinb |
Injection, Rimabotulinumtoxinb, 100 units |
PA Request |
4/1/23 |
Neurotoxin |
J0220 |
N/A |
Alglucosidase Alfa |
Injection, Alglucosidase alfa, 10 mg |
PA Request |
4/1/23 |
Enzyme Deficiency |
J9044 |
N/A |
Bortezomib |
Inj, Bortezomib, nos, 0.1 mg |
PA Request |
4/1/23 |
Oncology |
J7330 |
N/A |
MACI implant |
Autologous Cultured Chondrocytes, implant |
PA Request |
1/1/23 |
Osteoarthritis |
Q4082 |
N/A |
Misc |
Drug or Biological, not otherwise classified, Part B Drug Competitive Acquisition Program (CAP) |
PA Request |
1/1/23 |
Misc |
J9314 |
N/A |
Pemetrexed (Teva) |
Injection, Pemetrexed (Teva) not therapeutically equivalent to J9305, 10 mg |
PA Request |
8/1/23 |
Oncology |
J9048 |
N/A
|
Bortezomib (Fresenius Kabi) |
Injection, Bortezomib (Fresenius Kabi), not therapeutically equivalent to j9041, 0.1 mg |
PA Request |
8/1/23 |
Oncology |
J9049 |
N/A
|
Bortezomib (Hospira) |
Injection, Bortezomib (Hospira), not therapeutically equivalent to j9041, 0.1 mg |
PA Request |
8/1/23 |
Oncology |
J9046 |
N/A
|
Bortezomib (Dr. Reddy's) |
Injection, Bortezomib, (Dr. Reddy's), not therapeutically equivalent to j9041, 0.1 mg |
PA Request |
8/1/23 |
Oncology |
J0893 |
N/A
|
Decitabine (Sun) |
Injection, Decitabine (Sun Pharma) not therapeutically equivalent to j0894, 1 mg |
PA Request |
8/1/23 |
Oncology |
J9394 |
N/A
|
Fulvestrant (Fresnius) |
Injection, Fulvestrant (Fresenius Kabi) not therapeutically equivalent to j9395, 25 mg |
PA Request |
8/1/23 |
Oncology |
J9393 |
N/A
|
Fulvestrant (Teva) |
Injection, Fulvestrant (Teva) not therapeutically equivalent to j9395, 25 mg |
PA Request |
8/1/23 |
Oncology |
J1458 |
Naglazyme |
Galsulfase |
Injection, Galsulfase, 1 mg |
PA Request |
4/1/23 |
Enzyme Deficiency |
J2506 |
Neulasta |
Pegfilgrastim |
Injection, Pegfilgrastim, excludes biosimilar, 0.5 mg |
PA Request |
4/1/23 |
Neutropenia |
J1442 |
Neupogen |
Filgrastim |
Injection, Filgrastim (G-CSF), (Neupogen) excludes biosimilars, 1 mcg |
PA Request |
4/1/23 |
Neutropenia |
J0219 |
Nexviazyme |
Avalglucosidase Alfa-Ngpt |
Injection, Avalglucosidase alfa-ngpt, 4 mg |
PA Request |
4/1/23 |
Enzyme Deficiency |
Q5110 |
Nivestym |
Filgrastim-Aafi |
Injection, Filgrastim-aafi, biosimilar, (Nivestym), 1 microgram |
PA Request |
8/1/23 |
Neutropenia |
J3490 |
Not Otherwise Classified |
Unclassified drugs |
Drugs Unclassified injection |
PA Request |
4/1/23 |
Misc |
J3590 |
Not Otherwise Classified |
Unclassified biologics |
Unclassified Biologics |
PA Request |
1/1/23 |
Misc |
J2796 |
Nplate |
Romiplostim |
Injection, Romiplostim, 10 mg |
PA Request |
4/1/23 |
Thrombocytopenia |
J2182 |
Nucala |
Mepolizumab |
Injection, Mepolizumab, 1 mg |
PA Request |
4/1/23 |
Asthma |
J0485 |
Nulojix |
Belatacept |
Injection, Belatacept, 1 mg |
PA Request |
4/1/23 |
Immunosuppresive Agent |
Q5122 |
Nyvepria |
Pegfilgrastim-Apgf |
Injection, Pegfilgrastim-apgf (Nyvepria), biosimilar, 0.5 mg |
PA Request |
8/1/23 |
Neutropenia |
J2350 |
Ocrevus |
Ocrelizumab |
Injection, Ocrelizumab, 1 mg |
PA Request |
4/1/23 |
Multiple Sclerosis |
Q5114 |
Ogivri |
Trastuzumab-dkst |
Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg |
No PA/No Precert Required |
N/A |
Oncology |
Q5112 |
Ontruzant |
Trastuzumab-dttb |
Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg |
No PA/No Precert Required |
N/A |
Oncology |
J9299 |
Opdivo |
Nivolumab |
Injection, Nivolumab, 1 mg |
PA Request |
4/1/23 |
Oncology |
J0129 |
Orencia |
Abatacept |
Injection, Abatacept, 10 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J7324 |
Orthovisc |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose |
PA Request |
4/1/23 |
Osteoarthritis |
J9306 |
Perjteta |
Pertuzumab |
Injection, Pertuzumab, 1 mg |
PA Request |
4/1/23 |
Oncology |
J9316 |
Phesgo |
Pertuzumab / Trastuzumab / Hyaluronidase-Zzxf |
Injection, Pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg |
PA Request |
4/1/23 |
Oncology |
J9204 |
Poteligeo |
Mogamulizumab-Kpkc |
Injection, Mogamulizumab-kpkc, 1 mg |
PA Request |
4/1/23 |
Oncology |
J0897 |
Prolia |
Denosumab |
Injection, Denosumab, 1 mg |
PA Request |
4/1/23 |
Osteoporosis |
J1301 |
Radicava |
Edaravone |
Injection, Edaravone, 1 mg |
PA Request |
4/1/23 |
Amyotrophic Lateral Sclerosis (ALS) |
J0896 |
Reblozyl |
Luspatercept-Aamt |
Injection, Luspatercept-aamt 0.25mg |
PA Request |
4/1/23 |
Myelodysplastic Syndrome (MDS) |
J3489 |
Reclast |
Zoledronic acid |
Injection, zoledronic acid, 1 mg |
No PA/No Precert Required |
N/A |
Endocrine Disorders |
Q5125 |
Releuko |
Filgrastim-ayow, |
Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram |
No PA/No Precert Required |
N/A |
Neutropenia |
J1745 |
Remicade |
Infliximab |
Injection, Infliximab, excludes biosimilar, 10 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
Q5104 |
Renflexis |
Infliximab-Abda |
Injection, Infliximab-Abda, biosimilar, (Renflexis), 10 mg |
PA Request |
8/1/23 |
Auto-Inflammatory Conditions |
Q5105, Q5106 |
Retacrit |
Epoetin alfa-epbx |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units |
No PA/No Precert Required |
N/A |
Anemia |
Q5123 |
Riabni |
Rituximab-Arrx |
Injection, Rituximab-arrx, biosimilar, (riabni), 10 mg |
PA Request |
8/1/23 |
Oncology |
J9312 |
Rituxan |
Infliximab |
Injection, Rituximab, 10 mg |
PA Request |
4/1/23 |
Oncology |
J9311 |
Rituxan Hycela |
Rituximab/Hyaluronidase |
Injection, Rituximab 10 mg and hyaluronidase |
PA Request |
4/1/23 |
Oncology |
Q5119 |
Ruxience |
Rituximab-Pvvr |
Injection, Rituximab-pvvr, biosimilar, (ruxience), 10 mg |
PA Request |
8/1/23 |
Oncology |
Q5119 |
Ruxience |
Rituximab-pvvr |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg |
No PA/No Precert Required |
N/A |
Auto-inflammatory Conditions |
J2353 |
Sandostatin LAR |
Octreotide |
Injection, Octreotide, Depot Form for Intramuscular Injection, 1 Mg |
PA Request |
4/1/23 |
Endocrine Disorders |
J1602 |
Simponi Aria |
Golimumab |
Injection, Golimumab, 1 mg, for intravenous use |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J2327 |
Skyrizi |
Risankizumab |
Injection, Risankizumab-Rzaa, intravenous, 1 mg |
PA Request |
8/1/23 |
Auto-Inflammatory Conditions |
J7331 |
Sodium Hyaluronate |
Hyaluronan or derivative |
Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg |
No PA/No Precert Required |
N/A |
Osteoarthritis |
J1300 |
Soliris |
Eculizumab |
Injection, Eculizumab, 10 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J1930 |
Somatuline Depot |
Lanreotide |
Injection, Lanreotide, 1 mg |
PA Request |
4/1/23 |
Endocrine Disorders |
J2326 |
Spinraza |
Nusinersen |
Injection, Nusinersen, 0.1 mg |
PA Request |
4/1/23 |
Spinal Muscular Atrophy |
J3358 |
Stelara IV |
Ustekinumab |
Ustekinumab, for intravenous injection, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J3357 |
Stelara SC |
Ustekinumab |
Ustekinumab, for subcutaneous injection, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J7321 |
Supartz-FX |
Hyaluronan or derivative |
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose |
No PA/No Precert Required |
N/A |
Osteoarthritis |
J1627 |
Sustol |
Granisetron (Extended-Release) |
Injection, Granisetron, extended-release, 0.1 mg |
PA Request |
4/1/23 |
Anti-emetic |
J7331 |
Synojoynt |
Hyaluronan or derivative |
Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg |
No PA/No Precert Required |
N/A |
Osteoarthritis |
J7325 |
Synvisc |
Hyaluronan or derivative |
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg |
No PA/No Precert Required |
N/A |
Osteoarthritis |
J7325 |
Synvisc-One |
Hyaluronan or derivative |
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg |
No PA/No Precert Required |
N/A |
Osteoarthritis |
J9022 |
Tecentriq |
Atezolizumab |
Injection, Atezolizumab,10 mg |
PA Request |
4/1/23 |
Oncology |
J3241 |
Tepezza |
Teprotumumab-Trbw |
Injection, Teprotumumab-trbw, 10 mg |
PA Request |
4/1/23 |
Thyroid Eye Disease (TED) |
J2356 |
Tezspire |
Tezepelumab-Ekko |
Injection, Tezepelumab-ekko, 1 mg |
PA Request |
4/1/23 |
Asthma |
Q5116 |
Trazimera |
Trastuzumab-qyyp |
Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg |
No PA/No Precert Required |
N/A |
Oncology |
J9033 |
Treanda |
Bendamustine |
Injection, Bendamustine hcl (treanda), 1 mg |
PA Request |
4/1/23 |
Oncology |
J3315 |
Trelstar |
Triptorelin Pamoate |
Injection, Triptorelin Pamoate 3.75 mg (Trelstar) |
PA Request |
4/1/23 |
Oncology |
J1628 |
Tremfya |
Guselkumab |
Injection, Guselkumab, 1 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J1443 |
Triferic |
Ferric Pyrophosphate Citrate |
Injection, ferric pyrophosphate citrate solution (triferic), 0.1 mg of iron |
No PA/No Precert Required |
N/A |
Anemia |
J1444 |
Triferic |
Ferric Pyrophosphate Citrate |
Injection, ferric pyrophosphate citrate powder, 0.1 mg of iron |
No PA/No Precert Required |
N/A |
Anemia |
J1445 |
Triferic AVNU |
Ferric Pyrophosphate Citrate |
Injection, ferric pyrophosphate citrate solution (triferic avnu), 0.1 mg of iron |
No PA/No Precert Required |
N/A |
Anemia |
J7332 |
Triluron |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Triluron, for intra-articular injection, 1 mg |
PA Request |
4/1/23 |
Osteoarthritis |
J3316 |
Triptodur |
Triptorelin |
Injection, Triptorelin, extended-release, 3.75 mg |
PA Request |
4/1/23 |
Oncology |
J7329 |
Trivisc |
Hyaluronan Or Derivative |
Hyaluronan or derivative, Trivisc, for intra-articular injection, 1 mg |
PA Request |
4/1/23 |
Osteoarthritis |
J9317 |
Trodelvy |
Sacituzumab Govitecan-Hziy |
Injection, Sacituzumab Govitecan-Hziy, 2.5 Mg |
PA Request |
4/1/23 |
Oncology |
Q5115 |
Truxima |
Rituximab-Abbs |
Injection, Rituximab-abbs, biosimilar, (Truxima), 10 mg |
PA Request |
8/1/23 |
Oncology |
J2323 |
Tysabri |
Natalizumab |
Injection, Natalizumab, 1 mg |
PA Request |
4/1/23 |
Multiple Sclerosis |
Q5111 |
Udenyca |
Pegfilgrastim-Cbqv |
Injection, Pegfilgrastim-cbqv (Udenyca), biosimilar, 0.5 mg |
PA Request |
8/1/23 |
Neutropenia |
J1303 |
Ultomiris |
Ravulizumab |
Injection, Ravulizumab-cwvz, 10 mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J9399 |
Unclassified Drugs or Biologicals |
Chemotherapy Drugs |
Chemotherapy Drugs |
PA Request |
1/1/23 |
Oncology |
J1823 |
Uplizna |
Inebilizumab-Cdon |
Injection, Inebilizumab-cdon, 1 Mg |
PA Request |
4/1/23 |
Auto-Inflammatory Conditions |
J9303 |
Vectibix |
Panitumumab |
Injection, Panitumumab, 10 mg |
PA Request |
4/1/23 |
Oncology |
Q5129 |
Vegzelma |
Bevacizumab-Adcd |
Injection, Bevacizumab-adcd (vegzelma), biosimilar, 10 mg |
PA Request |
8/1/23 |
Oncology |
J9041 |
Velcade |
Bortezomib |
Injection, Bortezomib (velcade), 0.1 mg |
PA Request |
4/1/23 |
Oncology |
J1756 |
Venofer |
Iron Sucrose |
Injection, iron sucrose, 1 mg |
No PA/No Precert Required |
N/A |
Anemia |
J1427 |
Viltepso |
Viltolarsen |
Injection, Viltolarsen, 10 mg |
PA Request |
1/1/23 |
Duchenne Muscular Dystrophy (DMD) |
J7321 |
Visco-3 |
Hyaluronan or derivative |
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose |
No PA/No Precert Required |
N/A |
Osteoarthritis |
J3396 |
Visudyne |
Verteporfin |
Injection, Verteporfin, 0.1 Mg |
PA Request |
4/1/23 |
Ophthalmic Disorders |
J3385 |
Vpriv |
Velaglucerase Alfa |
Injection, Velaglucerase alfa, 100 units |
PA Request |
4/1/23 |
Enzyme Deficiency |
J3032 |
Vyepti |
Eptinezumab |
Injection, Eptinezumab-jjmr, 1 mg |
PA Request |
4/1/23 |
Neurotoxin |
J1429 |
Vyondys 53 |
Golodirsen |
Injection, Golodirsen, 10 mg |
PA Request |
1/1/23 |
Duchenne Muscular Dystrophy (DMD) |
J0588 |
Xeomin |
Incobotulinumtoxin A |
Injection, Incobotulinumtoxin a, 1 unit |
PA Request |
4/1/23 |
Neurotoxin |
J0775 |
Xiaflex |
Collagenase, Clostridium Histolyticum |
Injection, Collagenase, clostridium histolyticum, 0.01 mg |
PA Request |
4/1/23 |
Enzyme |
J2357 |
Xolair |
Omalizumab |
Injection, Omalizumab, 5 mg |
PA Request |
4/1/23 |
Asthma |
J9228 |
Yervoy |
Ipilimumab |
Injection, Ipilimumab, 1 mg |
PA Request |
4/1/23 |
Oncology |
Q5101 |
Zarxio |
Filgrastim-Sndz |
Injection, filgrastim-sndz, biosimilar, (Zarxio) 1 microgram |
PA Request |
8/1/23 |
Neutropenia |
J9223 |
Zepzelca |
Lurbinectedin |
Injection, Lurbinectedin, 0.1 Mg |
PA Request |
4/1/23 |
Oncology |
Q5120 |
Ziextenzo |
Pegfilgrastim-Bmez |
Injection, Pegfilgrastim-bmez, (Ziextenzo), biosimilar, 0.5 mg |
PA Request |
8/1/23 |
Neutropenia |
J0565 |
Zinplava |
Bezlotoxumab |
Injection, Bezlotoxumab, 10 mg |
PA Request |
4/1/23 |
Passive Immunizing and Treatment Agent |
Q5118 |
Zirabev |
Bevacizumab-Bvzr |
Injection, Bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg |
PA Request |
8/1/23 |
Oncology |
J2405 |
Zofran |
Ondansetron |
Injection, ondansetron hydrochloride |
No PA/No Precert Required |
N/A |
Anti-emetics |
J3489 |
Zoledronic Acid |
Zoledronic acid |
Injection, zoledronic acid, 1 mg |
No PA/No Precert Required |
N/A |
Endocrine Disorders |
J3399 |
Zolgensma |
Onasemnogene abeparvovec |
Injection, Onasemnogene Abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes |
PA Request |
4/1/23 |
Spinal Muscular Atrophy |